Fosmidomycin
Based on 2 publication(s) in Google Scholar
Fosmidomycin is an orally active antibiotic, which exhibits antimalarial activity through inhibition of 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DOXP reductoisomerase). Fosmidomycin inhibits P. falciparum strains 3D7, HB3, Dd2 and A2, with IC50s of 150, 71, 170 and 150 ng/mL, respectively. Fosmidomycin exhibits synergistic effect with Clindamycin (HY-B1455), and ameliorates malaria in mouse model.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 66508-53-0
- 分子式: C4H10NO5P
- 分子量:183.10
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 Fosmidomycin
MoreAntibiotic アイソフォーム固有の製品をすべて表示
MoreParasite アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MRC5 | IC50 |
>62 μM
Compound: 1
|
Cytotoxicity against human MRC5 cells
Cytotoxicity against human MRC5 cells
|
[PMID: 21866890] |
化学情報
-
CAS 番号 66508-53-0
-
分子量 183.10
-
分子式 C4H10NO5P
-
SMILES
OP(O)(CCCN(C=O)O)=O
-
Structure Classification
-
Initial Source
Streptomyces lavendulae
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Plant Sci
Adjusting function of camphor on primary metabolism in Cinnamomum camphora stressed by high temperature. [Abstract]2024 Feb:339:111956. PMID: 38101618 -
ACS Infect Dis
Integral Solvent-Induced Protein Precipitation for Target-Engagement Studies in Plasmodium falciparum. [Abstract]2024 Dec 13;10(12):4073-4086. PMID: 39631773
プロトコル
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Fosmidomycin 関連分類
HY-134914 関連分類
Powered by Bioz